RDC Bifunctional Chelators

Bifunctional chelators (BFCs) are core structural components of radiometal-based radiopharmaceuticals because they provide a stable linkage between a metallic radionuclide and a biologically active targeting vector^[1]. The primary biological role of a BFC is not target recognition itself, but preservation of radiometal coordination under physiological conditions while maintaining the biological properties of the carrier molecule^[1]. Mechanistically, BFCs participate in the coordination chemistry that governs radiolabeling efficiency, complex stability, and resistance to transchelation or metal release in vivo^[1][2]. These properties directly influence biodistribution, target-to-background ratios, and the suitability of radiopharmaceuticals for molecular imaging or radionuclide therapy^[1]. In oncology-focused applications, BFC-containing radiopharmaceuticals have been widely developed for positron emission tomography (PET), single-photon emission computed tomography (SPECT), and endoradiotherapy, where stable radiometal retention is a prerequisite for accurate targeting and therapeutic performance^[1][2]. Compared with related chelator classes, both acyclic and macrocyclic BFCs have been employed, with chelator selection guided by the coordination requirements of specific radiometals and the need for high thermodynamic stability and kinetic inertness^[1]. For experimental applications, commonly used platforms include DOTA-, NOTA-, DTPA-, and related chelator frameworks that enable attachment to peptides, antibodies, and other targeting molecules for preclinical and clinical radiopharmaceutical development^[1][2].